OSO BioPharmaceuticals Manufacturing has been granted research and analytical licenses by the U.S. Drug Enforcement Administration (DEA) to handle Schedule II through V controlled substances. “As a highly disciplined CMO, OsoBio is comfortable with the processes, controls and documentation required when working with especially sensitive pharmaceutical materials,” said Dr. Stuart Rose, president and chief executive officer of Albuquerque, NM-based OSOBio. The DEA places strict guidelines on the...